Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussion focused on the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
The discussion highlighted real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Case Study
Stewart, MD, described an 83-year-old woman with diabetic macular edema (DME) who had undergone temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
He is a professor and the chairman emeritus of ophthalmology at Mayo Clinic in Jacksonville, Florida, and the Knights Templar Eye Foundation Inc. Professor in Ophthalmology Research.
Author's summary: Emerging anti-VEGF agents improve retinal disease treatment.
More News
- Mineola loses playoff tiebreaker - Wood County Monitor
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Mineola, Quitman bands advance - Wood County Monitor
- How to watch Texas high school football: Malakoff vs. Mount Vernon, Oct. 31
- When An Infant Spoke and the Apostles Stayed Silent: A Lesson for the Modern Age
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Fashion lovers step out for Carol Byrne X Very Partywear Edit
- Ahsoka Season 2 Gets Exciting Update From Rosario Dawson
- Pat McGrath: The visionary behind beauty' s most defining moments